Incyte/$INCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Ticker
$INCY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2,617
ISIN
US45337C1027
Website
Incyte Metrics
BasicAdvanced
$13B
694.87
$0.10
0.90
-
Price and volume
Market cap
$13B
Beta
0.9
52-week high
$82.15
52-week low
$53.56
Average daily volume
1.9M
Financial strength
Current ratio
2.111
Quick ratio
1.747
Long term debt to equity
0.89
Total debt to equity
1.012
Interest coverage (TTM)
83.55%
Management effectiveness
Return on assets (TTM)
2.00%
Return on equity (TTM)
0.47%
Valuation
Price to earnings (TTM)
694.872
Price to revenue (TTM)
3.046
Price to book
3.56
Price to tangible book (TTM)
3.84
Price to free cash flow (TTM)
46.552
Growth
Revenue change (TTM)
17.13%
Earnings per share change (TTM)
-97.06%
3-year revenue growth (CAGR)
12.32%
3-year earnings per share growth (CAGR)
-71.51%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Incyte News
AllArticlesVideos
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
Business Wire·3 days ago
Incyte to Present at Upcoming Investor Conference
Business Wire·1 week ago
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Incyte stock?
Incyte (INCY) has a market cap of $13B as of June 06, 2025.
What is the P/E ratio for Incyte stock?
The price to earnings (P/E) ratio for Incyte (INCY) stock is 694.87 as of June 06, 2025.
Does Incyte stock pay dividends?
No, Incyte (INCY) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Incyte dividend payment date?
Incyte (INCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Incyte?
Incyte (INCY) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.